Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REScUE-OLE: Long-term Extension of Ustekinumab in Crohn's Disease
NCT05299931Phase 3Completed
- Sponsor
- Belgian IBD Research and Development
- Start
- Sep 2021
- Primary completion
- May 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of ustekinumab in Crohn's disease, sponsored by Belgian IBD Research and Development. Started Sep 2021; status: completed.
02
Drugs
ustekinumab
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NCT05299931.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05299931.